BioNexus Gene Lab Corp. Foreign Currency Transaction Gain (Loss), before Tax
BioNexus Gene Lab Corp. (BGLC) reported Foreign Currency Transaction Gain (Loss), before Tax of -$208.47 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-18.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2021-05-18
- BioNexus Gene Lab Corp. foreign currency transaction gain (loss), before tax for the quarter ending 2021-03-31 was -$208.47K.
- BioNexus Gene Lab Corp. foreign currency transaction gain (loss), before tax for the quarter ending 2020-09-30 was $21.94K.
- BioNexus Gene Lab Corp. foreign currency transaction gain (loss), before tax for the quarter ending 2020-06-30 was $3.49K.
- BioNexus Gene Lab Corp. foreign currency transaction gain (loss), before tax for the quarter ending 2020-03-31 was -$294.70K, a 1818.85% decline year-over-year.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 3 month as first filed | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | -$208.47K 10-Q · filed 2021-05-18 | ||||
| 2020-09-30 | $21.94K 10-Q/A · filed 2020-11-09 | $25.43K derived: sum of 2 quarters · filed 2020-11-09 | -$16.25K 10-Q/A · filed 2020-11-09 | -$248.14K derived: sum of 4 quarters · filed 2021-05-18 | |
| 2020-06-30 | $3.49K 10-Q/A · filed 2020-11-09 | -$38.19K 10-Q · filed 2020-08-11 | -$270.08K derived: sum of 3 quarters · filed 2021-05-18 | -$280.88K derived: sum of 4 quarters · filed 2021-05-18 | |
| 2020-03-31 | -$294.70K 10-Q · filed 2021-05-18 | -$41.68K 10-Q · filed 2020-05-08 | -$273.57K derived: sum of 2 quarters · filed 2021-05-18 | -$284.37K derived: sum of 3 quarters · filed 2021-05-18 | -$301.97K derived: sum of 4 quarters · filed 2021-05-18 |
| 2019-12-31 | $21.13K derived: 10-Q/A 12 month − 10-Q/A 9 month · filed 2020-11-09 | $10.33K derived: sum of 2 quarters · filed 2020-11-09 | -$7.27K derived: sum of 3 quarters · filed 2020-11-09 | $9.87K 10-Q/A · filed 2020-11-09 | |
| 2019-09-30 | -$10.80K 10-Q/A · filed 2020-11-09 | -$28.40K derived: sum of 2 quarters · filed 2020-11-09 | -$11.26K 10-Q/A · filed 2020-11-09 | ||
| 2019-06-30 | -$17.60K 10-Q · filed 2020-08-11 | -$455.00 10-Q · filed 2020-08-11 | |||
| 2019-03-31 | $17.14K 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |